Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller, Antoine Italiano, Steven Kao, Sarina A Piha-Paul, Jean-Pierre Delord, Robert R McWilliams, David A Fabrizio, Deepti Aurora-Garg, Lei Xu, Fan Jin, Kevin Norwood, Yung-Jue Bang

Open source

DOI: 10.1016/s1470-2045(20)30445-9
Published: 2020-10
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-20-30445-9,
  title = {Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study},
  author = {Aurélien Marabelle and Marwan Fakih and Juanita Lopez and Manisha Shah and Ronnie Shapira-Frommer and Kazuhiko Nakagawa and Hyun Cheol Chung and Hedy L Kindler and Jose A Lopez-Martin and Wilson H Miller and Antoine Italiano and Steven Kao and Sarina A Piha-Paul and Jean-Pierre Delord and Robert R McWilliams and David A Fabrizio and Deepti Aurora-Garg and Lei Xu and Fan Jin and Kevin Norwood and Yung-Jue Bang},
  year = {2020},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(20)30445-9},
  url = {https://doi.org/10.1016/s1470-2045(20)30445-9}
}

RIS

TY  - JOUR
TI  - Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
AU  - Aurélien Marabelle
AU  - Marwan Fakih
AU  - Juanita Lopez
AU  - Manisha Shah
AU  - Ronnie Shapira-Frommer
AU  - Kazuhiko Nakagawa
AU  - Hyun Cheol Chung
AU  - Hedy L Kindler
AU  - Jose A Lopez-Martin
AU  - Wilson H Miller
AU  - Antoine Italiano
AU  - Steven Kao
AU  - Sarina A Piha-Paul
AU  - Jean-Pierre Delord
AU  - Robert R McWilliams
AU  - David A Fabrizio
AU  - Deepti Aurora-Garg
AU  - Lei Xu
AU  - Fan Jin
AU  - Kevin Norwood
AU  - Yung-Jue Bang
PY  - 2020
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(20)30445-9
UR  - https://doi.org/10.1016/s1470-2045(20)30445-9
ER  -

APA

Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., Italiano, A., Kao, S., Piha-Paul, S. A., Delord, J., McWilliams, R. R., Fabrizio, D. A., Aurora-Garg, D., Xu, L., Jin, F., Norwood, K., & Bang, Y. (2020). Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30445-9

Source records

crossref · retrieved 2026-09-26T02:29:17.446Z